Aarti Pharmalabs Limited (AARTIPHARM)
Outcome of Board Meeting held on August 07, 2026.
Press Release - Q1FY27
- Standalone revenue 5.35bn +42.5% y-y; PAT 0.71bn +49.4% y-y
- Consolidated revenue 5.36bn +38.7% y-y; PAT 0.76bn +65.3% y-y
- Approved Rs 149 Cr capex for intermediate block capacity addition within 1 year
- Change in roles: Rashesh C. Gogri to MD, Hetal Gogri Gala to Executive Director from Oct 1, 2026
- Committees reconstituted effective Oct 1, 2026 (Audit, CSR, Stakeholders)
- Capacity expansion to serve intermediate & CDMO customers
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AARTIPHARM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AARTIPHARM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Aarti Pharmalabs Limited
Important.
The summary above is generated automatically from Aarti Pharmalabs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.